2026 Q2 -tulosraportti
UUTTA
4 päivää sitten
‧1 t 9 min
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 päivää sittenThat's not bad at all. Teva delivered a strong Q2 with revenue of $4.1 bn., where innovative brands again pulled their weight with 43% growth and over $1 bn. in quarterly revenue. Austedo, Ajovy and Uzedy continue to transform Teva's portfolio, and the company raises 2026‑guidance for all three to a total of ~$3.7 bn. Generics fell as expected due to tougher Revlimid‑competition in the USA, while biosimilars and Europe show stable progress. The biggest news is that Teva discontinues the ADS‑program and switches to direct NYSE‑listing from September 14. This can increase liquidity, open for broader institutional access and in the long term provide the opportunity for inclusion in major indices – a clear structural boost for the stock. I think that's pretty cool.- In the long term, we should aim high. Overall: solid execution of the Pivot‑to‑Growth strategy, strong brand growth, an accelerating pipeline and a capital market decision that potentially can be a catalyst for the next leg up in the stock.
UG I can see that you are strong in pharma stocks. Have you looked at Viatris ? I think it in many ways resembles tevas turnarround. But in some ways cheaper.- 28.7.Piper Sandler Raises Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $44.00 LINK: https://www.marketbeat.com/instant-alerts/piper-sandler-raises-teva-pharmaceutical-industries-nyseteva-price-target-to-4400-2026-07-28/
- ·26.7.If I could only choose one important figure in TEVA's Q2 report, it would be Operating margin = EBIT margin = Operating margin. EBIT margin is defined as: EBIT / Revenue (e.g. in 2025: 2.944 / 17.204 = 17.1%) Teva, however, reported an official GAAP operating margin of 12.5% in 2025 — significantly below both historical levels and well below Teva's own target for 2025, which was ~26%. It is important to note that the 2025 figure is not affected by the Emalex acquisition; Emalex was first acquired in January 2026 and therefore affects the 2026 margin, not 2025. In other words, there's a fly in the ointment at Teva: the margin is significantly below target, and not everything in the case is positive yet. Precisely for this reason, I will follow the operating margin very closely in the Q2 report. Teva's entire Pivot to Growth strategy is based on the margin being significantly raised above historical levels. Teva's own guidance states: Operating margin ~26% in 2025 (they did not reach that target) Operating margin ~30% in 2027 The Q2 report will therefore be the first real test of whether the margin improvement has finally begun.
Thanks for your insightful views :-) In Q1-26, operating profit non-gaap is 24,0%, a small decrease from Q1-25, where it was 24,3%. While gaap margin rises from 13,3% to 16,4%. How do you view that? https://cdn.prod.nntech.io/company-events/reports/e0fbffd2-878b-357a-94ae-42d25d562ab2/presentation.pdf page 35 - ·23.7.An Elliott Wave update, as it looks after today's close on 23/7-26. Today we got a clear bullish engulfing pattern on the daily chart. It is a statistically strong reversal signal and most likely marks the end of the C-wave in the correction that began after the intraday peak at 37.35 on February 3. What initially looked like a possible contracting triangle has now developed into a clear A-B-C correction, and today's engulfing candle very clearly indicates that the C-wave has ended. The intraday flush down to 29.60, followed by a full-body engulfing close, is classic price behavior at the end of a correction. With that structure in place, the probability is high that wave (5) has started. But as always — time will tell. TA is a roadmap, not a crystal ball, and chart reading is a dynamic process. Here's the chart: https://schrts.co/NBJcRrfUI'm currently looking at options on TEVA. TEVA is clearly being held down by the options market ahead of the Q2 earnings report on 29/7. Max Pain has fallen during the week from approx. 32.5 to 31.0, which shows that market makers are neutralizing the price within a narrow range – close above the potential C-bottom at 29.60–30.15. This indicates that the market desires neither a rally nor a breakdown before the earnings report. Both price structure and options flow therefore indicate that Q2 will be the decisive test for whether the C-bottom is intact or if the correction should be extended. Q2 on 29/7 will be exciting and provide the answer.
- ·17.7.TEVA will release its earnings report on 29/7-26. Exciting test of the A-C line in a contracting triangle. Since the preliminary price peak on 3/2-26 at 37.35, I have closely followed the price from an Elliott Wave perspective, as Teva since the bottom at 7.09 on 31/5-23 has followed a clear Elliott Wave pattern. The peak on 3/2-26 marked the end of wave (3) of ((3)). After this comes a correction, wave (4) of ((3)). As far as I can see, that correction has been a contracting triangle, where waves A, B, C, D are clearly visible, and now the probably completed wave E, which likely ended with a bottom at 31.28. Over the last couple of days, an intensive test of the A-C line in the chart has taken place. But the line has held so far. Phase A-D at the top of the chart refers to Richard D. Wyckoff's methodology. If my interpretation is correct, and I can absolutely be wrong and have been before, then we are facing an upward impulse wave (5) of ((3)). And if my assumption is correct, then the minimum price target is 31.28 + 11.57 = 42.85 usd. But if the earnings report disappoints on 29/7, then we are in a completely different situation. Here are a couple of charts From the bottom at 7.09 to today: https://schrts.co/qKWZNfyf From Dec 2025 to today: https://schrts.co/ReCgqiZf During my summer vacation on lovely Anholt, I am re-reading "Elliott Wave Trading by Wayne Gorman and Jeffrey Kennedy". A must-read book for those who look to this chart methodology, which is unsurpassed in emotional markets. I am fully aware that TEVA, in a few years, from a purely fundamental-analytical perspective, will likely have an EPS of at least 5-6 usd.Chart reading is a dynamic process. The C-bottom at 30.80 from 18/6-26 has now clearly broken downwards. Unfortunately, we are probably no longer dealing with a contracting triangle. But "Unclassified correction in progress" as Elliott called it. The long-term, structural support is now at MA200 at 30.27. It will undoubtedly be tested, the question is how far below we will go. Here's the chart: https://schrts.co/bRzPuwFt
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
4 päivää sitten
‧1 t 9 min
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sittenThat's not bad at all. Teva delivered a strong Q2 with revenue of $4.1 bn., where innovative brands again pulled their weight with 43% growth and over $1 bn. in quarterly revenue. Austedo, Ajovy and Uzedy continue to transform Teva's portfolio, and the company raises 2026‑guidance for all three to a total of ~$3.7 bn. Generics fell as expected due to tougher Revlimid‑competition in the USA, while biosimilars and Europe show stable progress. The biggest news is that Teva discontinues the ADS‑program and switches to direct NYSE‑listing from September 14. This can increase liquidity, open for broader institutional access and in the long term provide the opportunity for inclusion in major indices – a clear structural boost for the stock. I think that's pretty cool.- In the long term, we should aim high. Overall: solid execution of the Pivot‑to‑Growth strategy, strong brand growth, an accelerating pipeline and a capital market decision that potentially can be a catalyst for the next leg up in the stock.UG I can see that you are strong in pharma stocks. Have you looked at Viatris ? I think it in many ways resembles tevas turnarround. But in some ways cheaper.
- 28.7.Piper Sandler Raises Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $44.00 LINK: https://www.marketbeat.com/instant-alerts/piper-sandler-raises-teva-pharmaceutical-industries-nyseteva-price-target-to-4400-2026-07-28/
- ·26.7.If I could only choose one important figure in TEVA's Q2 report, it would be Operating margin = EBIT margin = Operating margin. EBIT margin is defined as: EBIT / Revenue (e.g. in 2025: 2.944 / 17.204 = 17.1%) Teva, however, reported an official GAAP operating margin of 12.5% in 2025 — significantly below both historical levels and well below Teva's own target for 2025, which was ~26%. It is important to note that the 2025 figure is not affected by the Emalex acquisition; Emalex was first acquired in January 2026 and therefore affects the 2026 margin, not 2025. In other words, there's a fly in the ointment at Teva: the margin is significantly below target, and not everything in the case is positive yet. Precisely for this reason, I will follow the operating margin very closely in the Q2 report. Teva's entire Pivot to Growth strategy is based on the margin being significantly raised above historical levels. Teva's own guidance states: Operating margin ~26% in 2025 (they did not reach that target) Operating margin ~30% in 2027 The Q2 report will therefore be the first real test of whether the margin improvement has finally begun.Thanks for your insightful views :-) In Q1-26, operating profit non-gaap is 24,0%, a small decrease from Q1-25, where it was 24,3%. While gaap margin rises from 13,3% to 16,4%. How do you view that? https://cdn.prod.nntech.io/company-events/reports/e0fbffd2-878b-357a-94ae-42d25d562ab2/presentation.pdf page 35
- ·23.7.An Elliott Wave update, as it looks after today's close on 23/7-26. Today we got a clear bullish engulfing pattern on the daily chart. It is a statistically strong reversal signal and most likely marks the end of the C-wave in the correction that began after the intraday peak at 37.35 on February 3. What initially looked like a possible contracting triangle has now developed into a clear A-B-C correction, and today's engulfing candle very clearly indicates that the C-wave has ended. The intraday flush down to 29.60, followed by a full-body engulfing close, is classic price behavior at the end of a correction. With that structure in place, the probability is high that wave (5) has started. But as always — time will tell. TA is a roadmap, not a crystal ball, and chart reading is a dynamic process. Here's the chart: https://schrts.co/NBJcRrfUI'm currently looking at options on TEVA. TEVA is clearly being held down by the options market ahead of the Q2 earnings report on 29/7. Max Pain has fallen during the week from approx. 32.5 to 31.0, which shows that market makers are neutralizing the price within a narrow range – close above the potential C-bottom at 29.60–30.15. This indicates that the market desires neither a rally nor a breakdown before the earnings report. Both price structure and options flow therefore indicate that Q2 will be the decisive test for whether the C-bottom is intact or if the correction should be extended. Q2 on 29/7 will be exciting and provide the answer.
- ·17.7.TEVA will release its earnings report on 29/7-26. Exciting test of the A-C line in a contracting triangle. Since the preliminary price peak on 3/2-26 at 37.35, I have closely followed the price from an Elliott Wave perspective, as Teva since the bottom at 7.09 on 31/5-23 has followed a clear Elliott Wave pattern. The peak on 3/2-26 marked the end of wave (3) of ((3)). After this comes a correction, wave (4) of ((3)). As far as I can see, that correction has been a contracting triangle, where waves A, B, C, D are clearly visible, and now the probably completed wave E, which likely ended with a bottom at 31.28. Over the last couple of days, an intensive test of the A-C line in the chart has taken place. But the line has held so far. Phase A-D at the top of the chart refers to Richard D. Wyckoff's methodology. If my interpretation is correct, and I can absolutely be wrong and have been before, then we are facing an upward impulse wave (5) of ((3)). And if my assumption is correct, then the minimum price target is 31.28 + 11.57 = 42.85 usd. But if the earnings report disappoints on 29/7, then we are in a completely different situation. Here are a couple of charts From the bottom at 7.09 to today: https://schrts.co/qKWZNfyf From Dec 2025 to today: https://schrts.co/ReCgqiZf During my summer vacation on lovely Anholt, I am re-reading "Elliott Wave Trading by Wayne Gorman and Jeffrey Kennedy". A must-read book for those who look to this chart methodology, which is unsurpassed in emotional markets. I am fully aware that TEVA, in a few years, from a purely fundamental-analytical perspective, will likely have an EPS of at least 5-6 usd.Chart reading is a dynamic process. The C-bottom at 30.80 from 18/6-26 has now clearly broken downwards. Unfortunately, we are probably no longer dealing with a contracting triangle. But "Unclassified correction in progress" as Elliott called it. The long-term, structural support is now at MA200 at 30.27. It will undoubtedly be tested, the question is how far below we will go. Here's the chart: https://schrts.co/bRzPuwFt
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
2026 Q2 -tulosraportti
UUTTA
4 päivää sitten
‧1 t 9 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sittenThat's not bad at all. Teva delivered a strong Q2 with revenue of $4.1 bn., where innovative brands again pulled their weight with 43% growth and over $1 bn. in quarterly revenue. Austedo, Ajovy and Uzedy continue to transform Teva's portfolio, and the company raises 2026‑guidance for all three to a total of ~$3.7 bn. Generics fell as expected due to tougher Revlimid‑competition in the USA, while biosimilars and Europe show stable progress. The biggest news is that Teva discontinues the ADS‑program and switches to direct NYSE‑listing from September 14. This can increase liquidity, open for broader institutional access and in the long term provide the opportunity for inclusion in major indices – a clear structural boost for the stock. I think that's pretty cool.- In the long term, we should aim high. Overall: solid execution of the Pivot‑to‑Growth strategy, strong brand growth, an accelerating pipeline and a capital market decision that potentially can be a catalyst for the next leg up in the stock.UG I can see that you are strong in pharma stocks. Have you looked at Viatris ? I think it in many ways resembles tevas turnarround. But in some ways cheaper.
- 28.7.Piper Sandler Raises Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $44.00 LINK: https://www.marketbeat.com/instant-alerts/piper-sandler-raises-teva-pharmaceutical-industries-nyseteva-price-target-to-4400-2026-07-28/
- ·26.7.If I could only choose one important figure in TEVA's Q2 report, it would be Operating margin = EBIT margin = Operating margin. EBIT margin is defined as: EBIT / Revenue (e.g. in 2025: 2.944 / 17.204 = 17.1%) Teva, however, reported an official GAAP operating margin of 12.5% in 2025 — significantly below both historical levels and well below Teva's own target for 2025, which was ~26%. It is important to note that the 2025 figure is not affected by the Emalex acquisition; Emalex was first acquired in January 2026 and therefore affects the 2026 margin, not 2025. In other words, there's a fly in the ointment at Teva: the margin is significantly below target, and not everything in the case is positive yet. Precisely for this reason, I will follow the operating margin very closely in the Q2 report. Teva's entire Pivot to Growth strategy is based on the margin being significantly raised above historical levels. Teva's own guidance states: Operating margin ~26% in 2025 (they did not reach that target) Operating margin ~30% in 2027 The Q2 report will therefore be the first real test of whether the margin improvement has finally begun.Thanks for your insightful views :-) In Q1-26, operating profit non-gaap is 24,0%, a small decrease from Q1-25, where it was 24,3%. While gaap margin rises from 13,3% to 16,4%. How do you view that? https://cdn.prod.nntech.io/company-events/reports/e0fbffd2-878b-357a-94ae-42d25d562ab2/presentation.pdf page 35
- ·23.7.An Elliott Wave update, as it looks after today's close on 23/7-26. Today we got a clear bullish engulfing pattern on the daily chart. It is a statistically strong reversal signal and most likely marks the end of the C-wave in the correction that began after the intraday peak at 37.35 on February 3. What initially looked like a possible contracting triangle has now developed into a clear A-B-C correction, and today's engulfing candle very clearly indicates that the C-wave has ended. The intraday flush down to 29.60, followed by a full-body engulfing close, is classic price behavior at the end of a correction. With that structure in place, the probability is high that wave (5) has started. But as always — time will tell. TA is a roadmap, not a crystal ball, and chart reading is a dynamic process. Here's the chart: https://schrts.co/NBJcRrfUI'm currently looking at options on TEVA. TEVA is clearly being held down by the options market ahead of the Q2 earnings report on 29/7. Max Pain has fallen during the week from approx. 32.5 to 31.0, which shows that market makers are neutralizing the price within a narrow range – close above the potential C-bottom at 29.60–30.15. This indicates that the market desires neither a rally nor a breakdown before the earnings report. Both price structure and options flow therefore indicate that Q2 will be the decisive test for whether the C-bottom is intact or if the correction should be extended. Q2 on 29/7 will be exciting and provide the answer.
- ·17.7.TEVA will release its earnings report on 29/7-26. Exciting test of the A-C line in a contracting triangle. Since the preliminary price peak on 3/2-26 at 37.35, I have closely followed the price from an Elliott Wave perspective, as Teva since the bottom at 7.09 on 31/5-23 has followed a clear Elliott Wave pattern. The peak on 3/2-26 marked the end of wave (3) of ((3)). After this comes a correction, wave (4) of ((3)). As far as I can see, that correction has been a contracting triangle, where waves A, B, C, D are clearly visible, and now the probably completed wave E, which likely ended with a bottom at 31.28. Over the last couple of days, an intensive test of the A-C line in the chart has taken place. But the line has held so far. Phase A-D at the top of the chart refers to Richard D. Wyckoff's methodology. If my interpretation is correct, and I can absolutely be wrong and have been before, then we are facing an upward impulse wave (5) of ((3)). And if my assumption is correct, then the minimum price target is 31.28 + 11.57 = 42.85 usd. But if the earnings report disappoints on 29/7, then we are in a completely different situation. Here are a couple of charts From the bottom at 7.09 to today: https://schrts.co/qKWZNfyf From Dec 2025 to today: https://schrts.co/ReCgqiZf During my summer vacation on lovely Anholt, I am re-reading "Elliott Wave Trading by Wayne Gorman and Jeffrey Kennedy". A must-read book for those who look to this chart methodology, which is unsurpassed in emotional markets. I am fully aware that TEVA, in a few years, from a purely fundamental-analytical perspective, will likely have an EPS of at least 5-6 usd.Chart reading is a dynamic process. The C-bottom at 30.80 from 18/6-26 has now clearly broken downwards. Unfortunately, we are probably no longer dealing with a contracting triangle. But "Unclassified correction in progress" as Elliott called it. The long-term, structural support is now at MA200 at 30.27. It will undoubtedly be tested, the question is how far below we will go. Here's the chart: https://schrts.co/bRzPuwFt
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt